-
Yiling Pharmaceutical's Aniprofen Injection Formally Started Phase III Clinical Trial
Time of Update: 2021-04-18
On April 13, Yiling Pharmaceutical issued an announcement that the company's Phase III clinical trial plan for the company's 1.
From April 2019 to June 2020, the Phase II clinical trial was completed in 8 centers including the Third Xiangya Hospital of Central South University.
-
Microchip's "Cioroni Capsule" launches Phase III clinical trial for small cell lung cancer
Time of Update: 2021-04-18
Recently, the Insight database revealed that Microchip Bio-Sioroni Capsules has launched a Phase III clinical trial for the treatment of small cell lung cancer that has progressed or recurred after a 2-line system of chemotherapy.
-
BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use
Time of Update: 2021-04-18
On April 9, 2021, the CDE official website showed that BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use, and the indication is advanced solid tumors.
BGB-A1217 is a TIGIT monoclonal antibody developed by BeiGene.
-
Izcargo, a biological product that crosses the blood-brain barrier, was approved for the first time on the market
Time of Update: 2021-04-18
A few days ago, JCR Pharmaceuticals announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Izcargo (pabinafusp alfa) for the treatment of mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome).
Retrieved April 13, 2021, from /JCR-Pharmaceuticals-Announces-Approval-of-IZCARGO%C2%AE-Pabinafusp-Alfa-for-Treatment-of-MPS-II-Hunter-Syndrome-in-Japan
-
Inventory: 9 innovative drugs developed by Chinese companies have been declared for listing in the United States
Time of Update: 2021-04-18
Zebutinib is the first innovative oncology drug independently developed by a Chinese company and approved by the US FDA for marketing.
-
Rongchang Biological "Tetaxipu" is officially on sale!
Time of Update: 2021-04-18
In January 2020, Taltazep obtained the US FDA's Phase III clinical trial approval for the treatment of systemic lupus erythematosus in the United States, and obtained fast track qualification in April.
-
Diabetes drug market: Eli Lilly and Novo Nordisk compete fiercely, Sanofi exits
Time of Update: 2021-04-18
At that time, the FDA approved Ozempic (semaglutide subcutaneous injection) as a new indication for reducing adult type 2 The risk of cardiovascular events (MACE) in patients with diabetes and other cardiovascular diseases (CVD), including cardiovascular infarctions, non-fatal heart attacks, or non-fatal strokes.
-
Qilu will win $1.4 billion in large varieties!
Time of Update: 2021-04-18
Source: official website of the State Food and Drug Administration, Mi Nei. com database A few days ago, Qilu Pharmaceutical entered the administrative examination and approval stage with imtricitabine tenofovir tablets, which were submitted for production in the generic category 4, and is expected to be approved in the near future.
-
China-EU Mutual Recognition Agreement Boosts Xinjiang's Special Products to the International Market
Time of Update: 2021-04-18
In addition to the first batch of three geographical indication products that have achieved mutual recognition between China and Europe, four landmark brands including Aksu Apple, Cele Red Date, Yili Lavender and Bosihu Tengyu will be included in the scope of mutual recognition protection, helping Xinjiang to have more high-quality products.
-
Heavy files landed nationwide!
Time of Update: 2021-04-18
" According to the "Zhejiang Pharmaceutical Price and Recruitment Credit Evaluation System" and other documents, the Provincial Pharmaceutical Equipment Purchasing Center will report the credit rating results of relevant pharmaceutical companies as follows:The Lugua Polypeptide Injection of Harbin Yuheng Pharmaceutical Co.
-
How common are local and systemic reactions to the mRNA new crown vaccine?
Time of Update: 2021-04-18
From the day of each dose of vaccination (day 0) to day 7, subjects need to answer questions about local and systemic reactions (such as pain at the injection site, fatigue, headache) and whether there are adverse health events (such as receiving medical care) ).
-
National Health Commission: Encourage primary medical and health institutions to provide elderly care services
Time of Update: 2021-04-18
He pointed out that the National Health Commission supports and encourages qualified medical and health institutions, especially grassroots medical and health institutions, to carry out elderly care services and increase elderly beds.
-
Eli Lilly's Erbitux new dosing regimen is approved by the U.S. FDA for head and neck cancer and colorectal cancer
Time of Update: 2021-04-18
CompilenewbornRecently, the US FDA approved a new dosage regimen of Eli Lilly’s targeted anticancer drug Erbitux (cetuximab, cetuximab): 500mg/m2 as a 120-minute intravenous infusion, once every 2 weeks (Q2W), for treatment K-Ras wild-type, EGFR-positive metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN).
-
The "two-invoice system" and national procurement are advancing. Do pharmaceutical companies choose agents or self-operate for sales?
Time of Update: 2021-04-18
In 2021, the company has to reform, the first step is to lay off employees, and the second step is to change the provincial manager to an agent and return to the agency model.
-
Innovative drug development choices: stand alone or flourish?
Time of Update: 2021-04-18
The number of IPO listed companies has increased across the board, and the Science and Technology Innovation Board, Hong Kong Stocks, Main Board, and even U.
; Talent flow and technological blessing have also accelerated the increase in the number of innovative pharmaceutical companies in China, attracting attention.
-
R&D intensity of more than 1,200 listed companies: pharmaceutical companies take the top six, but risks also arise!
Time of Update: 2021-04-18
Although the recombinant anti-CD25 humanized monoclonal antibody Jiannipa and the initumumab ceptin, which was approved last year and entered the medical insurance, have not yet reached the market, Sansheng Guojian, which is prepared for a rainy day, is already laying out relevant key tracks.
-
Bristol-Myers Squibb and Merck announced the positive results of two major immunotherapies
Time of Update: 2021-04-18
Today, Bristol-Myers Squibb announced that its PD-1 inhibitor Opdivo (nivolumab, nivolumab), combined with chemotherapy or chemotherapy + anti-CTLA-4 monoclonal antibody Yervoy, as a first-line therapy in the treatment of unresectable advanced or The primary endpoint was reached in a phase 3 clinical trial in patients with metastatic esophageal squamous cell carcinoma (ESCC).
-
5 highlights of FDA drug approval in the second quarter of 2021
Time of Update: 2021-04-18
Last year, the company submitted a Supplemental New Drug Application (sNDA) for Nuplazid to the US FDA for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP), with a target action date of April 3, 2021.
-
The policy of online sales of prescription drugs has been implemented, and a large number of pharmaceutical companies ushered in positive...
Time of Update: 2021-04-18
Medical Network News, April 9th. On April 8, the National Development and Reform Commission and the Ministry of Commerce jointly issued the "Opinions on Supporting the Construction of Hainan Free Tr
-
Two injections of Renfu Medicine passed the consistency evaluation of generic drugs
Time of Update: 2021-04-18
According to the website of the State Drug Administration, only Yichang Renfu has obtained approval for the production of nalbuphine hydrochloride injection in China.
